Europe Single-Cell Multi-Omics Market: Analysis and Forecast, 2023-2033
This report will be delivered in 1-5 working days.
Introduction to Europe Single-Cell Multi-Omics Market
The Europe single-cell multi-omics market was valued at $0.35 billion in 2023 and is expected to reach $1.71 billion by 2033, growing at a CAGR of 17.23% during the forecast period 2023-2033. The market experiences growth due to several factors, including the increasing prevalence of large-scale genomics studies utilizing single-cell RNA sequencing (Sc-RNA), a shift towards personalized medicine using the single-cell multi-omics approach in disease screening and diagnostics, and the rising adoption of single-cell multi-omics in drug development.
Market Introduction
The Europe Single-Cell Multi-Omics Market is experiencing significant growth due to the advancements in genomics research and the increasing adoption of personalized healthcare. Researchers are leveraging single-cell multi-omics technologies to gain deeper insights into the molecular mechanisms of diseases, resulting in more precise diagnostics and treatments. Furthermore, these technologies are revolutionizing drug development by enabling highly targeted therapeutic approaches. Europe, with its robust healthcare infrastructure and research capabilities, is at the forefront of embracing single-cell multi-omics. Collaborations among academic institutions, biotech companies, and healthcare entities are driving innovation and expanding the scope of applications for these cutting-edge technologies, contributing to the market's expansion.
Market Segmentation:
Segmentation 1: by Country
Growth/Marketing Strategy: The Europe single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.
Competitive Strategy: The Europe single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
Introduction to Europe Single-Cell Multi-Omics Market
The Europe single-cell multi-omics market was valued at $0.35 billion in 2023 and is expected to reach $1.71 billion by 2033, growing at a CAGR of 17.23% during the forecast period 2023-2033. The market experiences growth due to several factors, including the increasing prevalence of large-scale genomics studies utilizing single-cell RNA sequencing (Sc-RNA), a shift towards personalized medicine using the single-cell multi-omics approach in disease screening and diagnostics, and the rising adoption of single-cell multi-omics in drug development.
Market Introduction
The Europe Single-Cell Multi-Omics Market is experiencing significant growth due to the advancements in genomics research and the increasing adoption of personalized healthcare. Researchers are leveraging single-cell multi-omics technologies to gain deeper insights into the molecular mechanisms of diseases, resulting in more precise diagnostics and treatments. Furthermore, these technologies are revolutionizing drug development by enabling highly targeted therapeutic approaches. Europe, with its robust healthcare infrastructure and research capabilities, is at the forefront of embracing single-cell multi-omics. Collaborations among academic institutions, biotech companies, and healthcare entities are driving innovation and expanding the scope of applications for these cutting-edge technologies, contributing to the market's expansion.
Market Segmentation:
Segmentation 1: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Growth/Marketing Strategy: The Europe single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.
Competitive Strategy: The Europe single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.
Some of the prominent names in this market are:
- Menarini Group
- QIAGEN NV
- Rarecells Diagnostics
- Scipio Bioscience
- Singleron Biotechnologies
Executive Summary
Scope of the Study
Research Methodology
1 MARKET
1.1 Global Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Overview
1.2.1 Key Findings
1.2.2 Current Market Scenario
1.2.2.1 For Researchers
1.2.2.2 For Diagnostics
1.3 Industry Outlook
1.3.1 Regulatory Framework
1.3.2 Patent Analysis
1.3.2.1 Awaited Technological Developments
1.3.2.2 Patent Filing Trend (by Country)
1.3.2.3 Patent Filing Trend (by Year)
1.3.3 Key Trends
1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
1.3.4 Opportunity Assessment
1.3.5 Product Benchmarking
1.3.6 Clinical Trials
1.4 COVID-19 Impact
1.4.1 Pre-COVID-19
1.4.2 During COVID-19
1.4.3 Post COVID-19
1.5 Business Dynamics
1.5.1 Impact Analysis
1.5.2 Business Drivers
1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
1.5.3 Business Restraints
1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
1.5.4 Business Opportunities
1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations
2 EUROPE
2.1 Europe
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Single-Cell Multi-Omics Market (by Country)
2.1.3.1.1 Germany
2.1.3.1.2 Italy
2.1.3.1.3 U.K.
2.1.3.1.4 Spain
2.1.3.1.5 France
2.1.3.1.6 Rest-of-Europe
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnership, Collaboration, and Business Expansion
3.1.2 Market Share Analysis
3.1.3 Growth Share Analysis
3.1.3.1 By Application
3.1.3.2 By Omics Type
3.1.3.3 By Product Type
3.1.4 Visual Graphics of the Companies
3.1.5 Multi-Omics Ecosystem Active Players
3.2 Company Profiles
3.2.1 Menarini Group
3.2.1.1 Company Overview
3.2.1.2 Role of Menarini Group in the Single-Cell Multi-Omics Market
3.2.1.3 Analyst Perspective
3.2.2 QIAGEN NV
3.2.2.1 Company Overview
3.2.2.2 Role of QIAGEN NV in the Single-Cell Multi-Omics Market
3.2.2.3 Financials
3.2.2.4 Analyst Perspective
3.2.3 Rarecells Diagnostics
3.2.3.1 Company Overview
3.2.3.2 Role of Rarecells Diagnostics in the Single-Cell Multi-Omics Market
3.2.3.3 Analyst Perspective
3.2.4 Scipio Bioscience
3.2.4.1 Company Overview
3.2.4.2 Role of Scipio Bioscience in the Single-Cell Multi-Omics Market
3.2.4.3 Analyst Perspective
3.2.5 Singleron Biotechnologies
3.2.5.1 Company Overview
3.2.5.2 Role of Singleron Biotechnologies in the Single-Cell Multi-Omics Market
3.2.5.3 Recent Developments
3.2.5.4 Analyst Perspective
Scope of the Study
Research Methodology
1 MARKET
1.1 Global Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Overview
1.2.1 Key Findings
1.2.2 Current Market Scenario
1.2.2.1 For Researchers
1.2.2.2 For Diagnostics
1.3 Industry Outlook
1.3.1 Regulatory Framework
1.3.2 Patent Analysis
1.3.2.1 Awaited Technological Developments
1.3.2.2 Patent Filing Trend (by Country)
1.3.2.3 Patent Filing Trend (by Year)
1.3.3 Key Trends
1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
1.3.4 Opportunity Assessment
1.3.5 Product Benchmarking
1.3.6 Clinical Trials
1.4 COVID-19 Impact
1.4.1 Pre-COVID-19
1.4.2 During COVID-19
1.4.3 Post COVID-19
1.5 Business Dynamics
1.5.1 Impact Analysis
1.5.2 Business Drivers
1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
1.5.3 Business Restraints
1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
1.5.4 Business Opportunities
1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations
2 EUROPE
2.1 Europe
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Single-Cell Multi-Omics Market (by Country)
2.1.3.1.1 Germany
2.1.3.1.2 Italy
2.1.3.1.3 U.K.
2.1.3.1.4 Spain
2.1.3.1.5 France
2.1.3.1.6 Rest-of-Europe
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnership, Collaboration, and Business Expansion
3.1.2 Market Share Analysis
3.1.3 Growth Share Analysis
3.1.3.1 By Application
3.1.3.2 By Omics Type
3.1.3.3 By Product Type
3.1.4 Visual Graphics of the Companies
3.1.5 Multi-Omics Ecosystem Active Players
3.2 Company Profiles
3.2.1 Menarini Group
3.2.1.1 Company Overview
3.2.1.2 Role of Menarini Group in the Single-Cell Multi-Omics Market
3.2.1.3 Analyst Perspective
3.2.2 QIAGEN NV
3.2.2.1 Company Overview
3.2.2.2 Role of QIAGEN NV in the Single-Cell Multi-Omics Market
3.2.2.3 Financials
3.2.2.4 Analyst Perspective
3.2.3 Rarecells Diagnostics
3.2.3.1 Company Overview
3.2.3.2 Role of Rarecells Diagnostics in the Single-Cell Multi-Omics Market
3.2.3.3 Analyst Perspective
3.2.4 Scipio Bioscience
3.2.4.1 Company Overview
3.2.4.2 Role of Scipio Bioscience in the Single-Cell Multi-Omics Market
3.2.4.3 Analyst Perspective
3.2.5 Singleron Biotechnologies
3.2.5.1 Company Overview
3.2.5.2 Role of Singleron Biotechnologies in the Single-Cell Multi-Omics Market
3.2.5.3 Recent Developments
3.2.5.4 Analyst Perspective
LIST OF FIGURES
Figure 1: An Overview of Single-Cell Multi-Omics Sequencing Technologies
Figure 2: Single-Cell Multi-Omics Market, Impact Analysis
Figure 3: Single-Cell Multi-Omics Market (by Region), $Billion, 2022 and 2033
Figure 4: Single-Cell Multi-Omics Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Single-Cell Multi-Omics Market, Patent Analysis (by Country), January 2018- March 2023
Figure 9: Single-Cell Multi-Omics Market, Patent Analysis (by Year), January 2018-December2022
Figure 10: Single-Cell Multi-Omics Market, Key Trends, Market Shift, 2022-2033
Figure 11: Single-Cell Multi-Omics Market, Impact Analysis
Figure 12: Global Data for Rare Diseases, 2020
Figure 13: Companies Using Multi-Omics Approach in Research and Development of Drugs and Vaccines
Figure 14: Advantages of Multi-Omics in Drug Discovery and Development
Figure 15: Cost of Single Cell Sequencing (by Company)
Figure 16: Some of the Advancements in Single-Cell Metabolomics
Figure 17: Single-Cell Multi-Omics Market Share (by Region)
Figure 18: Europe Single-Cell Multi-Omics Market, Incremental Opportunity (by Country), $Million, 2023-2033
Figure 19: Europe Single-Cell Multi-Omics Market, $Billion, 2022-2033
Figure 20: Europe Single-Cell Multi-Omics Market (by Country), % Share, 2022 and 2033
Figure 21: Germany Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 22: Italy Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 23: U.K. Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 24: Spain Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 25: France Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 26: Rest-of-Europe Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 27: Single-Cell Multi-Omics Market, Number of Key Developments and Strategies, January 2018-March 2023
Figure 28: Funding Activities, January 2018-March 2023
Figure 29: New Offerings, January 2018-March 2023
Figure 30: Mergers and Acquisitions, January 2018-March 2023
Figure 31: Partnership, Collaboration, and Business expansion, January 2018-March 2023
Figure 32: Single-Cell Multi-Omics Market, Company Revenue Share Analysis, $Billion, 2022
Figure 33: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Application), 2023-2033
Figure 34: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Omics Type), 2023-2033
Figure 35: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Product Type), 2023-2033
Figure 36: Single Cell Multi Omics Market, Visual Graphics of the Companies
Figure 37: Menarini Silicon Biosystems: Product Portfolio
Figure 38: QIAGEN NV: Product Portfolio
Figure 39: QIAGEN NV: Overall Financials, $Million, 2020-2022
Figure 40: QIAGEN NV: Net Revenue (by Segment), $Million, 2020-2022
Figure 41: QIAGEN NV: Net Revenue (by Region), $Million, 2020-2022
Figure 42: QIAGEN NV: R&D Expenditure, $Million, 2020-2020
Figure 43: Rarecells Diagnostics: Product Portfolio
Figure 44: Scipio Bioscience: Product Portfolio
Figure 45: Singleron Biotechnologies: Product Portfolio
Figure 1: An Overview of Single-Cell Multi-Omics Sequencing Technologies
Figure 2: Single-Cell Multi-Omics Market, Impact Analysis
Figure 3: Single-Cell Multi-Omics Market (by Region), $Billion, 2022 and 2033
Figure 4: Single-Cell Multi-Omics Market: Research Methodology
Figure 5: Primary Research Methodology
Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 7: Top-Down Approach (Segment-Wise Analysis)
Figure 8: Single-Cell Multi-Omics Market, Patent Analysis (by Country), January 2018- March 2023
Figure 9: Single-Cell Multi-Omics Market, Patent Analysis (by Year), January 2018-December2022
Figure 10: Single-Cell Multi-Omics Market, Key Trends, Market Shift, 2022-2033
Figure 11: Single-Cell Multi-Omics Market, Impact Analysis
Figure 12: Global Data for Rare Diseases, 2020
Figure 13: Companies Using Multi-Omics Approach in Research and Development of Drugs and Vaccines
Figure 14: Advantages of Multi-Omics in Drug Discovery and Development
Figure 15: Cost of Single Cell Sequencing (by Company)
Figure 16: Some of the Advancements in Single-Cell Metabolomics
Figure 17: Single-Cell Multi-Omics Market Share (by Region)
Figure 18: Europe Single-Cell Multi-Omics Market, Incremental Opportunity (by Country), $Million, 2023-2033
Figure 19: Europe Single-Cell Multi-Omics Market, $Billion, 2022-2033
Figure 20: Europe Single-Cell Multi-Omics Market (by Country), % Share, 2022 and 2033
Figure 21: Germany Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 22: Italy Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 23: U.K. Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 24: Spain Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 25: France Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 26: Rest-of-Europe Single-Cell Multi-Omics Market, $Million, 2022-2033
Figure 27: Single-Cell Multi-Omics Market, Number of Key Developments and Strategies, January 2018-March 2023
Figure 28: Funding Activities, January 2018-March 2023
Figure 29: New Offerings, January 2018-March 2023
Figure 30: Mergers and Acquisitions, January 2018-March 2023
Figure 31: Partnership, Collaboration, and Business expansion, January 2018-March 2023
Figure 32: Single-Cell Multi-Omics Market, Company Revenue Share Analysis, $Billion, 2022
Figure 33: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Application), 2023-2033
Figure 34: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Omics Type), 2023-2033
Figure 35: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Product Type), 2023-2033
Figure 36: Single Cell Multi Omics Market, Visual Graphics of the Companies
Figure 37: Menarini Silicon Biosystems: Product Portfolio
Figure 38: QIAGEN NV: Product Portfolio
Figure 39: QIAGEN NV: Overall Financials, $Million, 2020-2022
Figure 40: QIAGEN NV: Net Revenue (by Segment), $Million, 2020-2022
Figure 41: QIAGEN NV: Net Revenue (by Region), $Million, 2020-2022
Figure 42: QIAGEN NV: R&D Expenditure, $Million, 2020-2020
Figure 43: Rarecells Diagnostics: Product Portfolio
Figure 44: Scipio Bioscience: Product Portfolio
Figure 45: Singleron Biotechnologies: Product Portfolio
LIST OF TABLES
Table 1: Single-Cell Multi-Omics Market, Key Developments Analysis, January 2018-March 2023
Table 2: Key Questions Answered in the Report
Table 3: Single-Cell Multi-Omics Market: Global Regulatory Organization
Table 4: Single-Cell Multi-Omics Market, Product Benchmarking
Table 5: Single-Cell Multi-Omics Market, Ongoing Clinical Trials
Table 6: Single-Cell Multi-Omics Platforms Used in the Diagnosis of Disease
Table 7: Recent Collaborations between Technology Providers and Life Sciences Companies
Table 8: Europe Single-Cell Multi-Omics Market Dynamics, Impact Analysis
Table 9: Multi-Omics Ecosystem Active Players
Table 1: Single-Cell Multi-Omics Market, Key Developments Analysis, January 2018-March 2023
Table 2: Key Questions Answered in the Report
Table 3: Single-Cell Multi-Omics Market: Global Regulatory Organization
Table 4: Single-Cell Multi-Omics Market, Product Benchmarking
Table 5: Single-Cell Multi-Omics Market, Ongoing Clinical Trials
Table 6: Single-Cell Multi-Omics Platforms Used in the Diagnosis of Disease
Table 7: Recent Collaborations between Technology Providers and Life Sciences Companies
Table 8: Europe Single-Cell Multi-Omics Market Dynamics, Impact Analysis
Table 9: Multi-Omics Ecosystem Active Players
